Variable | Full cohort (n = 231) | Matched cohort (n = 170) | ||||
---|---|---|---|---|---|---|
Rehydrated group (n = 113) | Non-rehydrated group (n = 118) | SD a | Rehydrated group (n = 85) | Non-rehydrated group (n = 85) | SD a | |
Demographics | ||||||
 Age, years | 46.3 ± 14.1 | 46.5 ± 13.9 | −0.012 | 45.4 ± 13.6 | 46.7 ± 14.5 | −0.090 |
 Male sex | 48 (42.5%) | 51 (43.2%) | −0.015 | 32 (37.6%) | 37 (43.5%) | −0.118 |
 Body mass index, kg/m2 | 23.0 ± 3.0 | 23.4 ± 3.2 | −0.106 | 22.8 ± 3.2 | 23.1 ± 3.0 | −0.081 |
Charlson Comorbidity Index | 2.0 (2.0–3.0) | 2.0 (2.0–2.0) | 0.159 | 2.0 (2.0–2.0) | 2.0 (2.0–2.0) | −0.038 |
Features of PPGLs | ||||||
 With typical symptoms b | 70 (61.9%) | 58 (49.2%) | 0.262 | 47 (55.3%) | 44 (51.8%) | 0.072 |
 With elevated serum catecholamine | 80 (70.8%) | 73 (61.9%) | 0.196 | 54 (63.5%) | 56 (65.9%) | −0.052 |
 Maximal tumor diameter, cm | 5.0 (4.0–6.7) | 5.0 (3.9–6.9) | 0.011 | 5.0 (4.0–6.9) | 5.0 (4.0–6.8) | 0.041 |
 Origin of tumor |  |  | 0.002 |  |  | 0.113 |
  Adrenal gland | 88 (77.9%) | 92 (78.0%) |  | 62 (72.9%) | 66 (77.6%) |  |
  Paraganglia | 25 (22.1%) | 26 (22.0%) |  | 23 (27.1%) | 19 (22.3%) |  |
 Peak SBP before α-blockade, mm Hg | 180 (160–210) | 178 (140–200) | 0.253 | 180 (148–200) | 180 (150–205) | −0.055 |
Preoperative preparation | ||||||
 Type of α-blockade |  |  | −0.074 |  |  | 0.000 |
  Selective | 59 (52.2%) | 66 (55.9%) |  | 49 (57.6%) | 49 (57.6%) |  |
  Non-selective | 54 (47.8%) | 52 (44.1%) |  | 36 (42.4%) | 36 (42.4%) |  |
 Duration of α-blockade, days | 19.0 (13.5–30.0) | 17.0 (11.0–30.0) | 0.021 | 19.0 (13.0–30.0) | 20.0 (11.0–34.0) | −0.141 |
 β-blockade | 27 (23.9%) | 24 (20.3%) | 0.083 | 17 (20.0%) | 18 (21.2%) | −0.027 |
 Other antihypertensive therapy c | 38 (33.6%) | 41 (34.7%) | −0.024 | 31 (36.5%) | 30 (35.3%) | 0.025 |
Year of surgery | Â | Â | 0.419 | Â | Â | 0.026 |
 2004–2008 | 16 (14.2%) | 34 (28.8%) |  | 16 (18.8%) | 16 (18.8%) |  |
 2009–2013 | 37 (32.7%) | 34 (28.8%) |  | 28 (32.9%) | 27 (31.8%) |  |
 2014–2018 | 60 (53.1%) | 50 (42.4%) |  | 41 (48.2%) | 42 (49.4%) |  |
Intraoperative data | ||||||
 Surgical approach |  |  | −0.021 |  |  | 0.049 |
  Open | 41 (36.3%) | 44 (37.3%) |  | 34 (40.0%) | 32 (37.6%) |  |
  Laparoscopic d | 72 (63.7%) | 74 (62.7%) |  | 51 (60.0%) | 53 (62.4%) |  |
 Type of anesthesia |  |  | 0.070 |  |  | −0.072 |
  General | 69 (61.1%) | 68 (57.6%) |  | 49 (57.6%) | 52 (61.2%) |  |
  Epidural + general | 44 (38.9%) | 50 (42.4%) |  | 36 (42.4%) | 33 (38.8%) |  |
 Duration of surgery, min | 119 (70–164) | 131 (94–186) | −0.116 | 127 (79–-178) | 122 (78–183) | −0.006 |
 Dose of phentolamine, mg | 4.0 (0.0–14.5) | 2.0 (0.0–12.0) | 0.020 | 3.0 (0.0–13.0) | 2.0 (0.0–11.0) | 0.130 |
 Dose of esmolol, mg | 80.0 (0.0–200.0) | 50 (0.0–130.0) | 0.117 | 50.0 (0.0–180.0) | 60 (0.0–143.0) | −0.085 |
 Estimated blood loss, ml | 100 (50–500) | 100 (50–500) | −0.034 | 100 (50–500) | 100 (50–450) | −0.039 |